Zynerba Pharmaceuticals Inc announced on Tuesday that the experimental study of their cannabis-based gel Zygel that is supposed to treat genetic disorders failed. The study showed that the gel was not statistically significant in improving abnormal behavior in patients with a neurological disorder called Fragile X syndrome when compared to a placebo. The company’s share has plummeted from 48.5% to $3.37.

– Business & Financial News, U.S & International Breaking News | Reuters, Reuters Editorial, 06/30/2020 7:47:42 AM

Open article: https://www.reuters.com/article/us-zynerba-pharms-study/zynerbas-cannabis-based-drug-for-rare-genetic-disorder-fails-study-idUSKBN2411Q2